Anika Therapeutics | ANIK - Operating Profit


Anika Therapeutics reported $646K in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Abbott USD 1.85B 399M Mar/2026
Agenus USD 14.4M 19.26M Dec/2025
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Integra LifeSciences USD 11.47M 54.54M Mar/2026
Intrexon USD -60.84M 26.62M Jun/2024
J&J USD 6.62B 1.03B Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
Ligand Pharmaceuticals USD 60.33M 40.29M Mar/2026
MacroGenics USD -12.1M 30.74M Dec/2025
Merit Medical Systems USD 44.16M 10.04M Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.94B 239M Mar/2026
Smith & Nephew USD 440M 50M Dec/2025
Stryker USD 1.1B 867M Mar/2026
Surmodics USD 58K 5.7M Jun/2025
Veracyte USD 19.08M 5.55M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026
Zimmer Biomet Holdings USD 395.1M 92.2M Mar/2026